Skip to content
Screener

Enliven Therapeutics ELVN Q1 2026 earnings

Reported May 7, 2026 · Before market open

EPS-$0.38Beat by $0.06
EPS estimate-$0.44

Next report

Date not yet announced

Financials

Q1 2026

Income statement

See full
Operating income-$27.8M+12.2%
Net income-$23.6M+17.2%
EPS (diluted)-$0.38+33.3%

Balance sheet

See full
Cash & equivalents$132.2M+30.0%
Total debt$302.0K-56.9%
Total equity$453.4M+57.3%
Total assets$464.9M+53.6%

Cash flow

See full
Operating cash flow-$19.3M+20.0%
CapEx--100%
Free cash flow-$19.3M+20.1%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$2.34B+143%
Enterprise value$2.21B+156%

Returns & leverage

See full
Return on equity-26.6%-3.5pp
Debt / equity0×0.0×
Current ratio40.3×+19.3×

FAQ

When did Enliven Therapeutics report Q1 2026 earnings?
Enliven Therapeutics (ELVN) reported Q1 2026 earnings on May 7, 2026 before market open.
What were Enliven Therapeutics's Q1 2026 revenue and EPS?
Enliven Therapeutics reported eps of $-0.38 for Q1 2026.
Did Enliven Therapeutics beat estimates in Q1 2026?
EPS beat the consensus estimate of $-0.44 by $0.06.
How did Enliven Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 33.3% from $-0.57.
Where can I find Enliven Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-211921) and the 10-Q periodic report (0001193125-26-211982) directly on SEC EDGAR. The filing index links above go to sec.gov.